Role of Neurokinin-1 Receptor Antagonists in Chemotherapy-Induced Emesis: Summary of Clinical Trials

References

• Griffin A. M., Butow P. N., Coates A. S., Childs A. M., Ellis P. M., Dunn S. M., Tattersal M. H. On the receiving end. V. Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann. Oncol. 1996; 7: 189–195, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Osba D., Zee B., Warr D., Kaizer L., Latreille J., Pater J. Quality of life studies in chemotherapy induced emesis. Oncology 1996; 53(Suppl 1)92–95
   PubMedGoogle Scholar
• Laszlo J., Lucas V. S., Jr. Emesis as a critical problem in chemotherapy. N. Engl. J. Med. 1981; 305: 948–949, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Navari R. M., Kaplan H. G., Gralla R. J., Grunberg S. M., Palmer R., Fitts D. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine receptor antagonist, for the prevention of nausea and vomiting induced by high dose cisplatin. J. Clin. Oncol. 1994; 12: 2204–2210, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Navari R. M., Gandara D., Hesketh P., Hall S., Maillard J., Ritter H., Friedman D., Fitts D. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin induced emesis. J. Clin. Oncol. 1995; 13: 1242–1248, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Perez E. A. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy induced emesis. J. Clin. Oncol. 1995; 13: 1036–1043, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Morrow G. R., Hickok J. T., Rosenthal S. N. Progress in reducing nausea and emesis. Comparisons of ondansetron, granisetron, and tropisetron. Cancer 1995; 76: 343–357, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Mantovani G., Maccio A., Bianch A., Curreli L., Ghiani M., Proto E., Santona M. C. Comparison of granisetron versus ondansetron versus tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer; a randomized controlled trial. Cancer 1996; 77: 941–948, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Hesketh P., Navari R. M., Grote T., Gralla R., Hainsworth J., Kris M., Anthony L., Khovasteh A., Tapazoglou E., Benedict C., Hahne W. Double blind randomized comparison of the antiemetic efficacy of intravenous dolasetron and intravenous ondansetron in the prevention of acute cisplatin induced emesis in patients with cancer. J. Clin. Oncol. 1996; 14: 2242–2249, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• The Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N. Engl. J. Med. 1995; 332: 1–5, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hesketh P. J., Harvey W. H., Harker W. G., Beck T. M., Ryan T., Bricker L. J., Kishja J. A., Murphy W. K., Hainsworth J. D., Haley B. A randomized double blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high dose cisplatin induced emesis. J. Clin. Oncol. 1994; 12: 596–600, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Perez E. A., Navari R. M., Kaplan H. G., Gralla R. J., Grunberg S. M., Palmer R. H., Fitts D. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin induced emesis. Suppl. Care Cancer 1997; 5: 31–37, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kris M. G., Pendergrass K. B., Navari R. M., Grote T. H., Nelson A. M., Thomas V., Ferguson B. B., Alman D. S., Pizzo B. A., Baker T. W., Fernando I. V., Chernoff S. B. Prevention of acute emesis following high dose cisplatin with the combination of oral dolasetron and dexamethasone. J. Clin. Oncol. 1997; 15: 2135–2138, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Italian Group for Antiemetic Research. Double blind dose finding study of four intravenous doses of dexamethasone in the prevention of cisplatin induced acute emesis. J. Clin. Oncol. 1998; 16: 2937–2942
   PubMed Web of Science ®Google Scholar
• Beck T. M., York M., Chang A., Navari R. M., Harvey W. H., Meshad M., Griffin D., Wenta A. Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Cancer Investig. 1997; 15: 297–303, [CSA]
   PubMed Web of Science ®Google Scholar
• Kaizer L., Warr D., Hoskins P., Latreille J., Lofters W., Yau J., Palmer M., Zee B., Levy M., Pater J. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada clinical trials group. J. Clin. Oncol. 1994; 12: 1050–1057, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Navari R. M., Madajcwicz S., Anderson N., Tchekmedyian N. S., Whaley W., Garewal H., Beck T. M., Chang A. Y., Greenberg B., Caldwell K. C. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J. Clin. Oncol. 1995; 13: 2408–2416, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy and radiotherapy-induced emesis: results of perugia consensus conference. Ann. Oncol. 1998; 9: 811–819, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Latreille J., Pater J., Johnston D., Laberge F., Stewart D., Rusthoven J., Hoskins P., Findlay B., McMurtrie E., Yelle L., Williams C., Walde D., Ernst S., Dhaliwal H., Warr D., Shepherd F., Mee D., Nishimura L., Osoba D., Zee B. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J. Clin. Oncol. 1998; 16: 1174–1178, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• The Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N. Engl. J. Med. 2000; 342: 1554–1559, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kris M. G., Gralla R. J., Tyson L. B. Controlling delayed vomiting: double blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J. Clin. Oncol. 1989; 7: 108–114, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Italian Group for Antiemetic Research. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin induced delayed emesis. J. Clin. Oncol. 1997; 15: 124–130
   PubMed Web of Science ®Google Scholar
• Gebbis V., Testa A., Valenza R., Cannata G., Tirrito M. L., Gabbia N. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. Cancer 1995; 76: 1821–1828
   PubMed Web of Science ®Google Scholar
• Pater J. L., Lofters W. S., Zee B., Dempsey E., Walde D., Moquin J. P., Wilson K., Hoskins P., Guevin R. M., Verma S., Navari R. M., Krook J. E., Hainsworth J., Palmer M., Chin C. The role of the 5 HT3 antagonists' ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann. Oncol. 1997; 8: 181–185, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Koo W. G., Ang P. T. Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann. Oncol. 1996; 7: 71–74, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kaizer L., Warr D., Hoskins P., Latreille J., Lofters W., Yau J., Palmer M., Zie B., Levy M., Pater J. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada trials group. J. Clin. Oncol. 1994; 12: 1050–1057, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Borison H. L., McCarthy L. E. Neuropharmacology of chemotherapy-induced emesis. Drugs 1983; 25(Suppl 1)8–17, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Longmore J., Swain C., Hill R. Neurokinin receptors. Drug News Perspect. 1995; 8: 5–23
   Google Scholar
• Snider R. M., Constantine J. W., Lowe J. A., Longo R. P., Lebel W. S., Woody H. A., Drozda S. E., Desai M. C., Viniok F. J., Spencer R. W. A potent nonpeptide antagonist of the substance P (NK-1) receptor. Science 1991; 251: 435–437, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Bountra C., Bruce K., Dale T., Garner C., Jordan C. T., Wissel D., Ward P. Anti-emetic profile of a non-peptide neurokinin NK-1 receptor antagonist, CP-99,994, in ferrets. Eur. J. Pharmacol. 1993; 249: R3–R4, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Watson J. W., Gonsalves S. F., Rossa A. A., McLean S., Seeger T., Obsach S., Andrews P. L. The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the nk1 receptor. Br. J. Pharmacol. 1995; 115: 84–94, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Beattie D. T., Beresford I. J., Connor H. E., Marshall F. H., Hawcock A. B., Hagan R. M., Bowers J., Birch P. J., Ward P. The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK-1 receptor antagonist. Br. J. Pharmacol. 1995; 116: 3149–3157, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Tattersall F. D., Rycroft W., Cumberbatch M., Mason G., Tye S., Williamson D. J., Hale J. J., Mills S. G., Finke P. E., MacCoss M., Sadowski S., Ber E., Cascieri M., Hill R. G., MacIntyre E., Hargreaves R. J. The novel NK-1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug L-758,298 inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology 2000; 39(4)652–663, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Gonsalves S., Watson J., Ashron C. Broad spectrum antiemetic effects of CP-122,721, a tachykinin NK-1 receptor antagonist in ferrets. Eur. J. Pharmacol. 1996; 305: 181–185, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kris M. G., Radford J. E., Pizzo B. A., Inabinet R., Hesketh A., Hesketh P. J. Use of a NK-1 receptor antagonist to prevent delayed emesis after cisplatin (letter). J. Natl. Cancer Inst. 1997; 89: 817–818, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cocquyt V., Van Belle S., Reinhardt R. R., Decramer M. L., O'Brien H., Schellens J. H., Borms M., Verseke L., VanAelst F., DeSmet M., Carides A. D., Eldridge K., Gertz B. J. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur. J. Cancer 2001; 37: 835–842, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Navari R. M., Reinhardt R. R., Gralla R. J., Kris M. G., Hesketh P. J., Khovasteth A., Kindler H., Grote T. H., Pendergrass K., Grunberg S. M., Carides A. D., Gertz B. J. Reduction of cisplatin-induced emesis by a selective neurokin-1 receptor antagonist. N. Engl. J. Med. 1999; 340: 190–195, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hesketh P. J., Gralla R. J., Webb R. T., Ueno W., Delprete S., Bachinsky M. E., Dirlani N. L., Stack C. B., Silberman S. L. Randomized phase II study of the neurokinin-1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J. Clin. Oncol. 1999; 17: 338–343, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Van Belle S., Liechinitser M., Navari R. M., Garin A. M., Decramer M. L., Riviera A., Thant M., Brestan E., Bui B., Eldridge K., DeSmet M., Michaels N., Reinhardt R. R., Carides A. D., Evans J. K., Gertz B. J. Prevention of cisplatin-induced emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 2002; 94: 3032–3041, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Campos D., Pereira J. R., Reinhardt R. R., Cardacedo C., Poli S., Vogel C., Martinel-Cedillo J., Erazo A., Wittreich J., Erikson L. O., Carides A. D., Gertz B. J. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J. Clin. Oncol. 2001; 19: 1759–1767, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Chawla S. P., Grunberg S. M., Gralla R. J., et al. Establishing the dose of the oral NK-1 antagonist aprepitant for chemotherapy induced nausea and vomiting. Cancer 2003; 97: 2290–2300, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hesketh P. J., Grunberg S. M., Gralla R. J., et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind placebo-controlled trial in patients receiving high-dose cisplatin–the aprepitant protocol 052 study group. J. Clin. Oncol. 2003; 21: 4112–4119, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Poli-Bigelli S., Rodrigues-Pereira J., Carides A. D., et al. Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy induced nausea and vomiting. Cancer 2003; 97: 3090–3098, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• deWitt R., Herrstedt J., Rapoport B. L., et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J. Clin. Oncol. 2003; 21: 4105–4111, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• deWitt R., Herrstedt J., Rapoport B. L., et al. The oral NK-1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycples of cisplatin-based chemotherapy: a combined analysis of two randomized, placebo-controlled phase III clinical trials. European. J. Cancer 2004; 40: 403–410, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Warr D. G., Eisenberg P., Hesketh P. J., et al. Phase III double-blind study to assess an aprepitant-containing regimen for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy. Proc. Am. Soc. Clin. Oncol. 2004, Abstract 8007
   PubMed Web of Science ®Google Scholar